656 related articles for article (PubMed ID: 32015028)
1. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
[TBL] [Abstract][Full Text] [Related]
2. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
[TBL] [Abstract][Full Text] [Related]
3. Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam.
Alsenani TA; Viviani SL; Kumar V; Taracila MA; Bethel CR; Barnes MD; Papp-Wallace KM; Shields RK; Nguyen MH; Clancy CJ; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0241421. PubMed ID: 35341315
[TBL] [Abstract][Full Text] [Related]
4. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
5. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.
Hemarajata P; Humphries RM
J Antimicrob Chemother; 2019 May; 74(5):1241-1243. PubMed ID: 30753572
[TBL] [Abstract][Full Text] [Related]
7. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
[TBL] [Abstract][Full Text] [Related]
8. Analyses of a Ceftazidime-Avibactam-Resistant
Castanheira M; Arends SJR; Davis AP; Woosley LN; Bhalodi AA; MacVane SH
mSphere; 2018 Sep; 3(5):. PubMed ID: 30258039
[TBL] [Abstract][Full Text] [Related]
9. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
[TBL] [Abstract][Full Text] [Related]
10. Meropenem/vaborbactam activity
Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
[TBL] [Abstract][Full Text] [Related]
12. Mutations in
Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
[TBL] [Abstract][Full Text] [Related]
13. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
[TBL] [Abstract][Full Text] [Related]
14. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
15.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
16. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
17.
Shields RK; Nguyen MH; Press EG; Chen L; Kreiswirth BN; Clancy CJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242667
[TBL] [Abstract][Full Text] [Related]
18. Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC β-Lactamase.
Taracila MA; Bethel CR; Hujer AM; Papp-Wallace KM; Barnes MD; Rutter JD; VanPelt J; Shurina BA; van den Akker F; Clancy CJ; Nguyen MH; Cheng S; Shields RK; Page RC; Bonomo RA
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0212421. PubMed ID: 35311523
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent
Shi Q; Shen S; Tang C; Ding L; Guo Y; Yang Y; Wu S; Han R; Yin D; Hu F
Emerg Microbes Infect; 2024 Dec; 13(1):2361007. PubMed ID: 38801099
[TBL] [Abstract][Full Text] [Related]
20. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.
Galani I; Karaiskos I; Angelidis E; Papoutsaki V; Galani L; Souli M; Antoniadou A; Giamarellou H
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):219-224. PubMed ID: 32729059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]